leisure time -WSS

leisure time

author：explore 2025-10-01 20:14:15 - browse：5

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Tuskegee Airman Raymond Cassagnol dies at 102

WSS

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

FDA panel endorses Alnylam’s heart drug — after picking it apart

Pig kidney works a record two months in donated body

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

WATCH: Why do bright lights make us see spots?

knowledge

leisure time

explore

Medicare details structure of new drug price negotiation program

Synthetic human embryos? Researchers say term is overblown

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Acelyrin, a rare IPO success, stumbles in its first big test

Affirmative action in medical school literally saved lives

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

Activists slam private health insurers over coverage restrictions

White House touts steps to stem shortages of cancer treatments

Alkermes shareholders re

New Covid vaccine is recommended for everyone 6 months or older

knowledge

Supreme Court strikes down Biden student loan forgiveness program

Synthetic human embryos? Researchers say term is overblown

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

UnitedHealth wins $3.3 billion takeover of Amedisys

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Supreme Court rules employers must be more accommodating of religious observance

Wikipedia

hotspot

leisure time

focus